970 filings
Page 3 of 49
NT 10-Q
SNGX
Soligenix Inc
14 Aug 23
Notice of late quarterly filing
4:09pm
ARS
2022 FY
SNGX
Soligenix Inc
7 Aug 23
Annual report to shareholders
4:09pm
DEFA14A
SNGX
Soligenix Inc
7 Aug 23
Additional proxy soliciting materials
4:07pm
DEF 14A
SNGX
Soligenix Inc
Definitive proxy
7 Aug 23
4:05pm
8-K
SNGX
Soligenix Inc
7 Jul 23
Departure of Directors or Certain Officers
4:05pm
8-K
SNGX
Soligenix Inc
23 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
SNGX
Soligenix Inc
26 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
10-Q
2023 Q1
SNGX
Soligenix Inc
Quarterly report
15 May 23
4:55pm
8-K
SNGX
Soligenix Inc
9 May 23
Soligenix Announces Pricing of $8.5 Million Public Offering
4:15pm
EFFECT
SNGX
Soligenix Inc
8 May 23
Notice of effectiveness
12:15am
424B4
SNGX
Soligenix Inc
5 May 23
Prospectus supplement with pricing info
6:43pm
4
Timothy R. Cote
5 May 23
SOLIGENIX / Timothy R. Cote ownership change
6:38pm
3
Timothy R. Cote
5 May 23
SOLIGENIX / Timothy R. Cote ownership change
6:25pm
S-1/A
SNGX
Soligenix Inc
IPO registration (amended)
4 May 23
5:30pm
CORRESP
SNGX
Soligenix Inc
4 May 23
Correspondence with SEC
12:00am
8-K
SNGX
Soligenix Inc
3 May 23
Strengthens regulatory and orphan drug development expertise
5:00pm
8-K
SNGX
Soligenix Inc
1 May 23
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease
7:45am
S-1/A
SNGX
Soligenix Inc
IPO registration (amended)
19 Apr 23
9:57pm
8-K
SNGX
Soligenix Inc
19 Apr 23
Entry into a Material Definitive Agreement
5:25pm
CORRESP
SNGX
Soligenix Inc
19 Apr 23
Correspondence with SEC
12:00am